Affiliation:
1. Center for Surveillance, Immunization, and Epidemiologic Research National Institute of Infectious Diseases Tokyo Japan
2. Department of Pathology National Institute of Infectious Diseases Tokyo Japan
3. Infectious Disease Emergency Specialist (IDES) Training Program Ministry of Health, Labour and Welfare Tokyo Japan
4. National Institute of Infectious Diseases Tokyo Japan
Abstract
AbstractBackgroundBased on routine surveillance data, Japan has been affected much less by COVID‐19 compared with other countries. To validate this, we aimed to estimate SARS‐CoV‐2 seroprevalence and examine sociodemographic factors associated with cumulative infection in Japan.MethodsA population‐based serial cross‐sectional seroepidemiological investigation was conducted in five prefectures in December 2021 (pre‐Omicron) and February–March 2022 (Omicron [BA.1/BA.2]‐peak). Anti‐nucleocapsid and anti‐spike antibodies were measured to detect infection‐induced and vaccine/infection‐induced antibodies, respectively. Logistic regression was used to identify associations between various factors and past infection.ResultsAmong 16 296 participants (median age: 53 [43–64] years), overall prevalence of infection‐induced antibodies was 2.2% (95% CI: 1.9–2.5%) in December 2021 and 3.5% (95% CI: 3.1–3.9%) in February–March 2022. Factors associated with past infection included those residing in urban prefectures (Tokyo: aOR 3.37 [95% CI: 2.31–4.91], Osaka: aOR 3.23 [95% CI: 2.17–4.80]), older age groups (60s: aOR 0.47 [95% CI 0.29–0.74], 70s: aOR 0.41 [95% CI 0.24–0.70]), being vaccinated (twice: aOR 0.41 [95% CI: 0.28–0.61], three times: aOR 0.21 [95% CI: 0.12–0.36]), individuals engaged in occupations such as long‐term care workers (aOR: 3.13 [95% CI: 1.47–6.66]), childcare workers (aOR: 3.63 [95% CI: 1.60–8.24]), food service workers (aOR: 3.09 [95% CI: 1.50–6.35]), and history of household contact (aOR: 26.4 [95% CI: 20.0–34.8]) or non‐household contact (aOR: 5.21 [95% CI:3.80–7.14]) in February–March 2022. Almost all vaccinated individuals (15 670/15 681) acquired binding antibodies with higher titers among booster dose recipients.ConclusionsBefore Omicron, the cumulative burden was >10 times lower in Japan (2.2%) compared with the US (33%), the UK (25%), or global estimates (45%), but most developed antibodies owing to vaccination.
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Epidemiology
Reference26 articles.
1. World Health Organization.Coronavirus disease (COVID‐19) pandemic. Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 24 October 2022.
2. Prevalence of SARS-CoV-2–Specific Antibodies, Japan, June 2020
3. Ministry of Health Labour and Welfare Japan.Results of the national seroprevalence study (in Japanese). Available from:https://www.mhlw.go.jp/content/000761671.pdfAccessed 24 October 2022.
4. Cabinet Public affairs office Cabinet Secretariat.About COVID‐19 vaccines (in Japanese). Available from:https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html. Accessed 24 October 2022.
5. World Health Organization.Population‐based age‐stratified seroepidemiological investigation protocol for coronavirus. Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 24 October 2022.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献